Back to results
US 7,622,116 B2Granted
Method of treating inflammation using soluble IL-17RCX4
AssigneeZymoGenetics, Inc.
InventorsRolf E. Kuestner, Zeren Gao, Steven D. Levin, Mark W. Rixon
Life of this patent
Estimating the term…
Abstract
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
Claims15
A method of treating a mammal afflicted with an inflammatory disease mediated by at least one of IL-17A and IL-17F, the method comprising:
- administering to the mammal afflicted with the inflammatory disease an effective amount of a soluble receptor polypeptide comprising an amino acid sequence as shown in residues 21 to 467 of SEQ ID NO:68,
- wherein the inflammatory activity of at least one of IL-17A and IL-17F in the mammal is reduced.
Dependencies are inferred from the claim text.